BRIEF-Exelixis says European commission approves Cabometyx By: Reuters: Company News September 14, 2016 at 01:15 AM EDT * European Commission approves Cabometyx tablets for the treatment of advanced renal cell carcinoma following VEGF-targeted therapy Read More >> Related Stocks: Exelixis Inc